Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the clinical management of cancer patients.



Press Releases

Prospective study on SCCA-IgM as predictor of HCC development in HCV+ cirrhotic patients presented at the 47th AISF Meeting.

Method to improve the diagnostic accuracy of PSA-IgM published in Cancer Biomarkers.

AIGO results on CEA-IgM presented at 18° FISMAD congress.

Serum levels of SCCA-IgM predict the efficacy of HCC treatments.

Multicenter prospective study on PSA-IgM to reduce negative prostatic mappings.

iXip - index for Prostate Cancer

Assessing prostate cancer risk


HepaIC - Assessment of the risk of HCC development in cirrhosis

Predicting HCC development in cirrhosis

Link

Follow Us

on linkedin

on facebook

on twitter
Xeptagen SpA. - P.iva: 07784560638 - Copyright © 2014. All rights reserved. For any problems, please contact webmaster@xeptagen.net

Username:
Password:

Forgot your password?